Saturday, August 15, 2026
Facts you can rely on·101 entities·4,805 sourced facts
Source-traceable intelligence

News you can rely on

Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.

What we're seeing

Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.

transformation· mixed

AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble

Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.

Brad LightcapOpenAI CodexAnthropicMinto Metals Corp.
transformation· mixed

Enterprise AI Agents Scale Fast, But Data Trust Gaps Push Value Toward Narrow Vertical Automation

Google Cloud survey data shows nearly universal enterprise intent to deploy agentic AI within two years, but adoption is bottlenecked by limited data access (an average of 45% of company data, and as little as 30% at 'data laggard' firms) and weak trust in agent decision accuracy. In response, large platform players (Microsoft, NVIDIA, Siemens, Mistral) are embedding agentic AI into governance and engineering workflows via enterprise partnerships, while a new wave of venture-backed vertical specialists (Maisa AI, Penguin AI, Casap) bypass the data-access problem by targeting narrow, well-defined back-office and administrative processes in finance and healthcare as the most immediately monetizable use case.

Scaling AI agents with trustworthy dataData leadersData laggardsManulife Financial Corporation
cycle· mixed

AI Chip Supercycle Hits a Valuation Correction as Consolidation and State Backing Accelerate

Despite strong underlying demand signals — SK hynix locking in long-term supply agreements and an expanded Nvidia partnership, KLA and other equipment makers still guiding forward, and Washington taking an equity stake in GlobalFoundries via a $300M CHIPS R&D award — semiconductor and AI infrastructure stocks suffered a broad late-July selloff, with leveraged AI-chip ETFs down sharply from their highs before a partial bounce (Micron +10% off lows). The sector is simultaneously consolidating (Skyworks-Qorvo naming a combined leadership team) and facing key-customer uncertainty (Apple's CEO transition from Tim Cook to John Ternus, plus a Gen4→Gen5 production node transition for its lead foundry customer), suggesting the market is repricing execution risk within an intact but maturing AI capex boom.

SK hynixNvidiaGlobalFoundries FotonixApple Cider Vinegar (Acetic Acid)
crisis· mixed

Fed Independence Under Political Pressure, Built on a Legacy of Crisis Management

Following two decades of Fed leadership credited with steering markets through Black Monday, the Asian and Russian financial crises, LTCM's collapse, and 9/11, the institution now faces a direct political challenge: a 2026 joint statement denouncing a probe targeting Chair Powell signals an escalating fight over central bank independence. Recurring congressional testimony from Fed officials on supervision, regulation, and innovation shows the institution simultaneously defending its autonomy while continuing routine oversight of monetary policy and financial regulation.

Jerome PowellAlan GreenspanMary BarraMax P. Bowman
cycle· mixed

AI Chip Supercycle Meets a Sharp Market Correction

Even as semiconductor fundamentals stay strong — record KLA results, new SK hynix supply agreements, a GlobalFoundries-DoC CHIPS partnership, AMD/Cerebras and Nvidia/SK hynix AI accelerator deals, and roadmapped AI chips through 2028 — a broad sell-off has hit AI infrastructure and chip stocks, with SOXX down 25% and leveraged semiconductor ETFs down 62% from highs. The divergence between continued AI buildout activity (partnerships, guidance, M&A like Skyworks-Qorvo) and deteriorating equity sentiment marks a classic late-cycle correction, with Micron's bounce off lows as a possible early stabilization signal.

iShares Semiconductor ETF (SOXX)KLA CorporationSK hynixGlobalFoundries Fotonix
transformation· mixed

Agentic AI Goes Enterprise: Partnerships Surge Ahead of Governance Readiness

Major enterprises and platforms (Siemens-NVIDIA, Microsoft-Manulife, Mistral-in-Copilot-Studio, Box) are racing to embed agentic AI into core industrial, financial, and administrative workflows, while a wave of new AI-native startups (Maisa AI, Penguin AI, Casap) target specific verticals like healthcare admin and business process automation. Survey data (Agentic Enterprise Report 2026) reveals this rollout is outpacing governance and change-management readiness, with large majorities of executives lacking clear ownership models or pre-deployment roadmaps.

NvidiaSiemens HealthineersMicrosoft AzureManulife Financial Corporation
Signals we're tracking
  • Satellite-Terrestrial Network Integration Acceleration

    Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

  • EPKINLY Regulatory-Clinical Success Cascade

    High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

  • Smart Home AI Platform Convergence

    Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products

  • AI Integration Acceleration

    Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances

Working hypotheses
  • NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools

    88% confidence · untested
  • Data center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers

    88% confidence · untested
  • LLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations

    85% confidence · untested
  • AI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance

    85% confidence · untested
  • Hyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026

    85% confidence · untested
Sources we've traced
all →
Source document

Nvidia just locked down deal that changes AI race

Nvidia just locked down deal that changes AI race South Korean President Lee Jae Myung flew to San Francisco on July 24 for a summit with the most powerful names in artificial intelligence…

Source document

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse  

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes at…

Source document

0G Labs Trained World's Largest Decentralized AI Model at 107B Parameters in 2025 - Eight Months Before This Week's Industry Headlines

0G Labs Trained World's Largest Decentralized AI Model at 107B Parameters in 2025 - Eight Months Before This Week's Industry Headlines San Francisco, CA, March 24, 2026 (GLOBE NEWSWIRE) -- While the crypto industry celebrated Bittensor's Covenant-72B this week as a breakthrough in decentralized AI training, 0G Labs had…

Source document

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS of $(7.26) Reiterate…

Source document

Claude Code costs up to $200 a month. Goose does the same thing for free.

VentureBeat AI - Enterprise Ai Title: Claude Code costs up to $200 a month. Goose does the same thing for free…

Source document

How Do You Define an AI Companion?

IEEE Spectrum - Technical Title: How Do You Define an AI Companion?…

Where sources disagree
all →
JPMorgan Chase & Co.

Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

General Motors Company

FACT A and FACT B report the SAME metric (revenue) for the SAME fiscal period (Q2 2026) at the SAME observation date (2026-06-30), but with values that differ by a factor of 1 million: $48.026 billion vs. $48,026. This is a data quality error — likely FACT B is missing six zeros or represents a different unit/scale entirely. For General Motors, the $48B figure (FACT A) is plausible quarterly revenue; the $48K figure (FACT B) is not.

General Motors Company

Same entity (General Motors), same attribute (revenue), same fiscal period (Q2 2026), same observation date (2026-06-30) but wildly different values: $48.026 billion vs. $91,650. The difference is approximately 523,000x. Fact A aligns with typical quarterly revenue for a major automaker; Fact B is implausibly small. This indicates a data quality issue—likely Fact B is either incorrectly scaled, mis-attributed (e.g., per-share, segment-level, or transaction-level data), or sourced from a corrupted record.

General Motors Company

Both facts report net_income for General Motors in Q2 2026 (observed 2026-06-30), but with vastly different values: $1,305,000,000 vs $3,932. The ~332,000x magnitude difference represents a direct value conflict for the identical metric, entity, and time period. This is not a change over time — both timestamps are the same.

General Motors Company

The same entity (General Motors), same attribute (net_income), same fiscal period (Q2 2026), and same observation timestamp (2026-06-30) report conflicting values: $1,305,000,000 USD vs $1,305 USD. These values differ by a factor of 1,000,000 and cannot both be accurate representations of Q2 2026 net income. This is a clear data quality issue—one value likely contains a missing scale multiplier or erroneous decimal placement.

Every fact is traceable to the document it came from — see how we source every claim.

Watch Live

Via News LiveLive
Loading stream...

Latest News

View All →
Alphabet Shares Fall as Dean, Ghemawat Exit to Found Discovery Loop While Hassabis Steps Back at DeepMind
Venture Investment Strategy

Alphabet Shares Fall as Dean, Ghemawat Exit to Found Discovery Loop While Hassabis Steps Back at DeepMind

Jeff Dean, Sanjay Ghemawat, and two other senior Google researchers left Alphabet within a single week to launch rival startup Discovery Loop, while Demis Hassabis stepped back from day-to-day DeepMind leadership. Alphabet shares fell on the news, even as the company moved to invest in the new startup rather than treat the departures as a pure loss.

Salvado
NVIDIA Infrastructure Deals With Thermo Fisher, Lilly Anchor Pharma's Shift to AI-Native Drug Discovery
Pharma Partnerships

NVIDIA Infrastructure Deals With Thermo Fisher, Lilly Anchor Pharma's Shift to AI-Native Drug Discovery

NVIDIA is expanding as an infrastructure provider to Thermo Fisher and Eli Lilly as a cluster of AI-native biotech platforms launches in 2026. Novo Nordisk posted strong Q1 2026 results while closing its internal cell therapy unit and licensing the asset to AI-native platform Cellular Intelligence, signaling top pharma is outsourcing discovery capability rather than building it in-house.

Salvado
Novo Nordisk Licenses Cell Therapy Program to AI Firm as Stock Rallies 25%
Pharma Strategy

Novo Nordisk Licenses Cell Therapy Program to AI Firm as Stock Rallies 25%

Novo Nordisk closed its internal cell therapy unit and licensed the program to AI-driven Cellular Intelligence instead of building it in-house, with shares up nearly 25% over 30 days. The move tracks a broader pharma shift toward licensing AI biology platforms rather than owning R&D outright, as firms like MindWalk, NVIDIA BioNeMo, Owkin and Boltz Lab compete to control the underlying data layer of drug discovery.

Salvado
Novo Nordisk Shuts Internal Cell Therapy Unit, Licenses Parkinson's Asset to AI Platform as Stock Gains 24.9%
Pharma Strategy

Novo Nordisk Shuts Internal Cell Therapy Unit, Licenses Parkinson's Asset to AI Platform as Stock Gains 24.9%

Novo Nordisk is closing its internal cell therapy program and licensing a Parkinson's asset to an AI-driven discovery platform, even as its stock climbs 24.9% over 30 days. The move reflects a broader pivot: pharma incumbents are reallocating R&D capital toward AI foundation-model platforms like NVIDIA BioNeMo and MindWalk's HYFT rather than building discovery capability internally.

Salvado
Built for machines, too

Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.

Get it as an API →